Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is currently trading at 238.15 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company specializing in Gynaecology, Orthopaedics, and Dermatology. It operates primarily in India, holding competitive positions in these key therapeutic areas. In FY26, the company experienced a 6% YoY revenue growth reaching ₹2,230 Mn, with an operational PAT increase of 12.5%. This demonstrates their continued profitability and resilience despite modest quarterly performance. The accumulation of a cash balance of ₹1,757 Mn indicates robust free cash flow generation, underscoring their strong financial position and capacity for strategic investment or distribution to shareholders. Jagsonpal focuses on maintaining strong brand equity. Its diversification into acquiring the Yash Pharma business has enhanced its portfolio, paving the path for further growth in attractive market segments. Innovations in their product pipeline and adherence to market demands are supported by partnerships and strategic product launches, strengthening their competitive edge in the pharmaceutical sector.

Over the past 52 weeks, Jagsonpal Pharmaceuticals Ltd has traded between a low of ₹154.90 and a high of ₹264.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Jagsonpal Pharmaceuticals Ltd has a market capitalization of approximately 1,570.78. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Jagsonpal Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 34.55 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,570.78 Cr, Jagsonpal Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Jagsonpal Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Jagsonpal Pharmaceuticals Ltd is 34.55. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Jagsonpal has signed an agreement to acquire an 85% equity stake in Aequitas Healthcare Private Limited for ₹20.8 crore in cash.

The board of Jagsonpal Pharmaceuticals has approved a buyback price of ₹250 per equity share through a tender offer.

The board of Jagsonpal Pharmaceuticals has approved a buyback of up to 16 lakh shares at a price of ₹250 per share, with a total maximum value of ₹40 crore. The buyback will be conducted through a tender offer.